Merck, Lycera broaden partnership on autoimmune disease drugs

Merck & Co. expanded a collaboration with Lycera to develop and market small-molecule drugs against autoimmune diseases. The deal entitles Lycera to an undisclosed upfront fee and research support plus more than $300 million in possible milestone fees, plus royalties. Merck will handle clinical development, and will get the global rights to marketing.

View Full Article in:

Genetic Engineering & Biotechnology News · Crain's Detroit Business (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA